News and Updates


Quay takes lead in production of “live” medicines in exciting Microbiome therapeutics space

Pharmaceutical outsourcing specialist Quay Pharma is continuing to invest in its pioneering work in live biotherapeutics with the establishment of specialist GMP suites at its facility in Deeside,...

Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients

Accelerated AC regimen-Doxorubicin 60 mg/m2,Cyclophosphamide 600 mg/m2 on day 1 & day 14 of each cycle along with G-CSF support for up to 4 cycles, followed by Paclitaxel 175 mg/m2 in the next 4...

Use of DENARASE® for tomorrow´s industry

Background & Motivation to use DENARASE® The removal of nucleic acids from biological samples is a necessary step for applications in Red Biotechnology and Molecular Biology. Along the production...

DENARASE® | Upgrading the Endonuclease from Serratia marcesce

>> Download the full article by clicking here << Appropriate handling and removal of nucleic acids is crucial for many applications in red biotechnology and molecular biology. Upon the...

AI to reshape bioprocessing and drug discovery say experts

Artificial intelligence (AI) will change biopharmaceutical discovery and manufacturing according to experts who say these data-rich processes are ideal for the application of computer-based learning...
Biopharmaceutical medicines article

Making a biomanufacturing team: challenges and strategies

Making biopharmaceutical medicines is a highly technical process that requires a diverse range of handling, production and process skills. Rapid growth of the sector, combined with the shortage of...
biopharma outsourcing

CDMO revenues reflect bio outsourcing surge says expert

Biopharmaceutical outsourcing has increased markedly in recent years with a greater volume of work previously kept in-house being handed over to third party contractors. The trend is evident in the...
bioprocessing tech

Pipelines, economics and IP: How bioprocessing tech firms assess markets

Epidemiology is a core skill for biopharmaceutical companies. Being able to identify an area of unmet medical need helps guide R&D strategy and, ultimately, is what shapes drug pipelines. It is...
bioLIVE Whitepaper - Opposite attract

bioLIVE Whitepaper | Opposites attract. Blurring the lines between small and large molecule manufacturing

bioLIVE's latest whitepaper collects finding from a panel of experts that have identified potential applications of small molecule expertise that should be applied to the biologics industry . Click...

Gene therapy: A complex and fast-evolving manufacturing challenge

Gene therapies could revolutionise the treatment of inherited diseases but firms hoping to follow Luxturna to market must remember that, from a manufacturing perspective, the field is still in its...

CDMOs primed for biologics boom

Outsourcing took longer to catch on in the biopharma sector than in the small molecule drug industry. Initially, biologic developers did production in-house with only activities like fill/finish...
bioLIVE breakfast session, people attending a meeting

Interview with Mary Lynn Bercik of NIBRT on the bioLIVE breakfast session at CPhI North America

At CPhI North America, we are hosting a breakfast meeting to provide a sneak peek of next year’s all-new event: BioLive . We caught up with one of our expert speakers, Mary Lynn Bercik of Johnson...